Prognostic significance of ING3 expression in patients with cancer: A systematic review and meta-analysis

Li, Zehan; Xu, Shengchao; Chen, Lin; Huang, Shuqi; Kuerban, Xieyida; Li, Tianyu

doi:10.3389/fonc.2023.1090860

Cited by 5 publications

(3 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 97 known protein-coding genes at these loci, many of the genes located at, or spanning the peak QTL are known to be associated directly with cancer development, or with cancer associated pathways. For example, Kcnd2, Tspan12, Ing3 and Cped1 located on Chromosome six are known to promote proliferation of breast cancer cells ( Yang et al, 2023 ), be a critical factor for cancer associated fibroblast mediated invasion ( Otomo et al, 2014 ), used as a potential biomarker for CRC/breast cancer ( Kim and Lee, 2022 ; Li et al, 2023 ) or confer oncogenic effects in prostate cancer ( Zhu et al, 2023 ) respectively. Likewise on chromosome 12, expression of Matn3, Osr1, and Nt5c1b have been associated with colon adenocarcinoma, gastric and breast cancer development ( Zhao Z. et al, 2023a ; Chi et al, 2023 ; Gadwal et al, 2023 ); potential use as a biomarker for breast cancer ( Li et al, 2020 ) or promotion of EMT and metastasis in breast cancer ( Wang et al, 2020 ; Li et al, 2021 ) and identified as a cancer testis-antigen in canine malignancies ( Nemec et al, 2019 ) respectively.…”

Section: Discussionmentioning

confidence: 99%

The MexTAg collaborative cross: host genetics affects asbestos related disease latency, but has little influence once tumours develop

Fisher,

Patrick,

Hoang

et al. 2024

Front. Toxicol.

View full text Add to dashboard Cite

Objectives: This study combines two innovative mouse models in a major gene discovery project to assess the influence of host genetics on asbestos related disease (ARD). Conventional genetics studies provided evidence that some susceptibility to mesothelioma is genetic. However, the identification of host modifier genes, the roles they may play, and whether they contribute to disease susceptibility remain unknown. Here we report a study designed to rapidly identify genes associated with mesothelioma susceptibility by combining the Collaborative Cross (CC) resource with the well-characterised MexTAg mesothelioma mouse model.Methods: The CC is a powerful mouse resource that harnesses over 90% of common genetic variation in the mouse species, allowing rapid identification of genes mediating complex traits. MexTAg mice rapidly, uniformly, and predictably develop mesothelioma, but only after asbestos exposure. To assess the influence of host genetics on ARD, we crossed 72 genetically distinct CC mouse strains with MexTAg mice and exposed the resulting CC-MexTAg (CCMT) progeny to asbestos and monitored them for traits including overall survival, the time to ARD onset (latency), the time between ARD onset and euthanasia (disease progression) and ascites volume. We identified phenotype-specific modifier genes associated with these traits and we validated the role of human orthologues in asbestos-induced carcinogenesis using human mesothelioma datasets.Results: We generated 72 genetically distinct CCMT strains and exposed their progeny (2,562 in total) to asbestos. Reflecting the genetic diversity of the CC, there was considerable variation in overall survival and disease latency. Surprisingly, however, there was no variation in disease progression, demonstrating that host genetic factors do have a significant influence during disease latency but have a limited role once disease is established. Quantitative trait loci (QTL) affecting ARD survival/latency were identified on chromosomes 6, 12 and X. Of the 97-protein coding candidate modifier genes that spanned these QTL, eight genes (CPED1, ORS1, NDUFA1, HS1BP3, IL13RA1, LSM8, TES and TSPAN12) were found to significantly affect outcome in both CCMT and human mesothelioma datasets.Conclusion: Host genetic factors affect susceptibility to development of asbestos associated disease. However, following mesothelioma establishment, genetic variation in molecular or immunological mechanisms did not affect disease progression. Identification of multiple candidate modifier genes and their human homologues with known associations in other advanced stage or metastatic cancers highlights the complexity of ARD and may provide a pathway to identify novel therapeutic targets.

show abstract

Section: Discussionmentioning

confidence: 99%

The MexTAg collaborative cross: host genetics affects asbestos related disease latency, but has little influence once tumours develop

Fisher,

Patrick,

Hoang

et al. 2024

Front. Toxicol.

View full text Add to dashboard Cite

show abstract

“…Past research demonstrated a close correlation between the occurrence of tumors and the immune status of the organism, with immune cells participating in various pathways involved in the initiation and progression of tumors. In previous studies on patients with malignant neoplasms such as lung cancer, esophageal cancer, colorectal cancer, and gastric cancer, researchers have detected decreased levels of CD3 + T cells, CD4 + T cells , NK cells, and CD4 + /CD8 + ratio in peripheral blood 4,[57][58][59][60] . The commonality among these findings reveals a prevalent state of immunosuppression in patients with malignant tumors, suggesting that changes in immune cell populations may be intimately associated with tumor burden in the body.…”

Section: Discussionmentioning

confidence: 99%

Predictive value of lymphocyte subsets and lymphocyte-to-monocyte ratio in assessing the efficacy of neoadjuvant therapy in breast cancer

Zhang,

Li,

Liu

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Lymphocyte subsets are the most intuitive expression of the body’s immune ability, and the lymphocyte-to-monocyte ratio (LMR) also clearly reflect the degree of chronic inflammation activity. The purpose of this study is to investigate their predictive value of lymphocyte subsets and LMR to neoadjuvant therapy (NAT) efficacy in breast cancer patients. In this study, lymphocyte subsets and LMR were compared between breast cancer patients (n = 70) and benign breast tumor female populations (n = 48). Breast cancer patients were treated with NAT, and the chemotherapy response of the breast was evaluated using established criteria. The differences in lymphocyte subsets and LMR were also compared between pathological complete response (pCR) and non-pCR patients before and after NAT. Finally, data were analyzed using SPSS. The analytical results demonstrated that breast cancer patients showed significantly lower levels of CD3 + T cells, CD4 + T cells, CD4 + /CD8 + ratio, NK cells, and LMR compared to benign breast tumor women (P < 0.05). Among breast cancer patients, those who achieved pCR had higher levels of CD4 + T cells, NK cells, and LMR before NAT (P < 0.05). NAT increased CD4 + /CD8 + ratio and decreased CD8 + T cells in pCR patients (P < 0.05). Additionally, both pCR and non-pCR patients exhibited an increase in CD3 + T cells and CD4 + T cells after treatment, but the increase was significantly higher in pCR patients (P < 0.05). Conversely, both pCR and non-pCR patients experienced a decrease in LMR after treatment. However, this decrease was significantly lower in pCR patients (P < 0.05). These indicators demonstrated their predictive value for therapeutic efficacy. In conclusion, breast cancer patients experience tumor-related immunosuppression and high chronic inflammation response. But this phenomenon can be reversed to varying degrees by NAT. It has been found that lymphocyte subsets and LMR have good predictive value for pCR. Therefore, these markers can be utilized to identify individuals who are insensitive to NAT early on, enabling the adjustment of treatment plans and achieving precise breast cancer treatment.

show abstract

“…Keywords: Esophageal cancer, Early detection, DNA methylation, Innovative approach, survival analysis, clinical implications Esophageal cancer is one of the foremost global causes of mortality [1]. There are two types of ESCA cancer: EAC (esophageal adenocarcinoma ( and squamous cell carcinoma (ESCC) [2]. EAC prevails in Western populations, whereas ESCC predominates in Asian nations, particularly China, with an incidence rate of 88.84 [3].…”

mentioning

confidence: 99%

Unlocking Esophageal Carcinoma’s Secrets: An integrated Omics Approach Unveils DNA Methylation as a pivotal Early Detection Biomarker with Clinical Implications

Ali,

Zhang,

Liu

2023

Preprint

View full text Add to dashboard Cite

1AbstractEsophageal carcinoma (EC) ranks among the top six most prevalent malignancies worldwide with a recent surge in incidence. An innovative integrated omics technique is presented for discerning the two primary types of esophageal carcinoma (EC) AND Squamous cell carcinoma and adenocarcinoma. Utilizing The Cancer Genome Atlas (TCGA) data via Bioconductor, the research integrated DNA methylation and RNA expression analyses for esophageal cancer (ESCA). Key findings revealed DNA methylation’s pivotal role in ESCA progression and its potential as an early detection biomarker. Significant disparities in methylation patterns offered insights into the disease’s pathogenesis. A comparison with the TCGA Pan-Cancer dataset using Bioconductor tools enriched the understanding of ESCA genomics. Specifically, 131,220 hypomethylated probes were detected in tumors compared to 6,248 in healthy tissues. Additionally, 42,060 probe-gene pairs linked methylation variations to expression alterations, with 768 hypomethylated motifs identified. Thirteen of these motifs emerged as potential diagnostic markers. Transcription factor analyses spotlighted crucial regulators, including NFL3, ATF4, JUN, and CEBPG, revealing intricate regulatory networks in ESCA. Survival statistics further correlated clinical factors with patient longevity. This research recommends an innovative approach to identifying oesophageal abnormalities through DNA methylation and gene expression mechanisms. Research suggests DNA methylation may serve as an early detection biomarker, aiding in identifying esophagus cancer prior to more advanced stages.

show abstract

Prognostic significance of ING3 expression in patients with cancer: A systematic review and meta-analysis

Cited by 5 publications

References 53 publications

The MexTAg collaborative cross: host genetics affects asbestos related disease latency, but has little influence once tumours develop

The MexTAg collaborative cross: host genetics affects asbestos related disease latency, but has little influence once tumours develop

Predictive value of lymphocyte subsets and lymphocyte-to-monocyte ratio in assessing the efficacy of neoadjuvant therapy in breast cancer

Unlocking Esophageal Carcinoma’s Secrets: An integrated Omics Approach Unveils DNA Methylation as a pivotal Early Detection Biomarker with Clinical Implications

Contact Info

Product

Resources

About